超声引导下电针刺激脊神经节治疗带状疱疹急性期疼痛的临床疗效

注册号:

Registration number:

ChiCTR2400094802 

最近更新日期:

Date of Last Refreshed on:

2024-12-27 15:18:09 

注册时间:

Date of Registration:

2024-12-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

超声引导下电针刺激脊神经节治疗带状疱疹急性期疼痛的临床疗效

Public title:

Clinical efficacy of ultrasound-guided electroacupuncture stimulation of spinal ganglia in the treatment of acute phase pain of herpes zoster

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下电针刺激脊神经节治疗带状疱疹急性期疼痛的临床疗效

Scientific title:

Clinical efficacy of ultrasound-guided electroacupuncture stimulation of spinal ganglia in the treatment of acute phase pain of herpes zoster

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘鑫 

研究负责人:

刘鑫 

Applicant:

Xin Liu  

Study leader:

Xin Liu  

申请注册联系人电话:

Applicant telephone:

+86 178 5582 2733

研究负责人电话:

Study leader's
telephone:

+86 178 5582 2733

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

fryylx11@163.com

研究负责人电子邮件:

Study leader's E-mail:

fryylx11@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市富阳区富春街道北环路429号

研究负责人通讯地址:

浙江省杭州市富阳区富春街道北环路429号

Applicant address:

No. 429, Beihuan Road, Fuchun Street, Fuyang District, Hangzhou, Zhejiang Province, China

Study leader's address:

No. 429, Beihuan Road, Fuchun Street, Fuyang District, Hangzhou, Zhejiang Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

杭州市富阳区第一人民医院

Applicant's institution:

The First People's Hospital of Fuyang District, Hangzhou

研究负责人所在单位:

杭州市富阳区第一人民医院

Affiliation of the Leader:

The First People's Hospital of Fuyang District, Hangzhou

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-LW伦审第(097)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

杭州市富阳区第一人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First People's Hospital of Fuyang District, Hangzhou, China

伦理委员会批准日期:

Date of approved by ethic committee:

2024-10-22 00:00:00

伦理委员会联系人:

杨菁

Contact Name of the ethic committee:

Jing Yang

伦理委员会联系地址:

杭州市富阳区富春街道北环路429号科教行政楼403室

Contact Address of the ethic committee:

Room 403, Science and Education Administration Building, No. 429 Beihuan Road, Fuchun Street, Fuyang District, Hangzhou, China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 6315 7868

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

杭州市富阳区第一人民医院

Primary sponsor:

The First People's Hospital of Fuyang District, Hangzhou

研究实施负责(组长)单位地址:

浙江省杭州市富阳区富春街道北环路429号

Primary sponsor's address:

No. 429, Beihuan Road, Fuchun Street, Fuyang District, Hangzhou, Zhejiang Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

杭州市富阳区

Country:

China

Province:

Zhejiang Province

City:

Fuyang District, Hangzhou

单位(医院):

杭州市富阳区第一人民医院

具体地址:

浙江省杭州市富阳区富春街道北环路429号

Institution
hospital:

The First People's Hospital of Fuyang District, Hangzhou

Address:

No. 429, Beihuan Road, Fuchun Street, Fuyang District, Hangzhou, Zhejiang Province, China

经费或物资来源:

患者自付

Source(s) of funding:

Patient pays

研究疾病:

带状疱疹性神经痛  

Target disease:

herpes zoster neuralgia (medicine)

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究超声引导下电针刺激脊神经节对急性期ZAP患者镇痛效果的影响。  

Objectives of Study:

To investigate the effect of ultrasound-guided electroacupuncture stimulation of spinal ganglia on the analgesic effect in patients with ZAP in the acute phase.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1、患有眼、耳、内脏、脑膜、泛发性或无疹型带状疱疹等特殊类型的患者。2、处于妊娠或哺乳期的妇女。3、对多种药物有过敏史的个体。4、瘢痕体质的患者。5、合并严重系统性疾病或全身衰竭的患者,包括恶性肿瘤、精神病、结缔组织病、血友病等。6、有出血倾向或已知血液疾病的患者。7、病情复杂,无法准确评估治疗效果和安全性的患者。

Exclusion criteria:

Patients with specific types of herpes zoster such as eye, ear, visceral, meningeal, generalized or rash-free.2 Women who are pregnant or breastfeeding.3 Individuals with a history of allergy to multiple medications.4 Patients with keloidal scarring.5 Patients with co-morbid severe systemic diseases or systemic failure including malignant tumors, psychiatric illnesses, connective tissue disorders, and hemophilia.6 Patients with a tendency to bleed or with known blood disorders.7 Patients with complex conditions that cannot be evaluated for safety.8 Patients who have a history of severe systemic diseases or generalized failure including malignancy, psychiatric disorders, connective tissue disease, and hemophilia. Patients with complex medical conditions that cannot be accurately assessed for therapeutic efficacy and safety.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2026-10-21 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2026-10-21 00:00:00

干预措施:

Interventions:

组别:

研究组

样本量:

33

Group:

research group

Sample size:

干预措施:

在口服常规药物的基础上行超声引导下电针刺激脊神经节,每次电针刺激时长为30分钟,每3天一次,连续干预5次。

干预措施代码:

Intervention:

Ultrasound-guided electroacupuncture stimulation of the spinal ganglia was performed on the basis of oral administration of conventional medications, with each electroacupuncture stimulation lasting 30 minutes, every 3 days, for 5 consecutive interventions.

Intervention code:

组别:

对照组

样本量:

35

Group:

control subjects

Sample size:

干预措施:

口服常规药物:盐酸伐昔洛韦颗粒冲服,300mg/次,每日两次,连续服用2周后停用。普瑞巴林胶囊,按照说明书推荐用法给药,起始剂量为75mg/次,每日两次,连续服用1周,1周后根据疗效及耐受性增加至每次150mg,每日两次后按该剂量服用1月为一疗程。塞来昔布胶囊200mg/次,每日两次,服用1月为一疗程。甲钴胺片,每次口服0.5mg,每天三次,1月为一疗程。

干预措施代码:

Intervention:

Oral conventional medication: valacyclovir hydrochloride granules flushed, 300mg/dose twice daily for 2 weeks and then discontinued. Pregabalin capsules, administered according to the recommended usage of the instruction manual, the starting dose is 75mg/dose, twice daily for 1 week, after 1 week, according to the efficacy and tolerability of the increase to 150mg per dose, twice daily, and then the dose is taken for 1 month as a course of treatment. Celecoxib capsule 200mg/dose twice daily for 1 month. Mecobalamin tablets, 0.5mg per oral dose, three times a day, 1 month for a course of treatment.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

杭州市富阳区 

Country:

China

Province:

Zhejiang Province

City:

Fuyang District, Hangzhou

单位(医院):

杭州市富阳区第一人民医院 

单位级别:

三级 

Institution
hospital:

The First People's Hospital of Fuyang District, Hangzhou

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

疼痛视觉模拟评分

指标类型:

主要指标

Outcome:

visual analogue scale,VAS

Type:

Primary indicator

测量时间点:

治疗前和治疗后1周、2周、1个月

测量方法:

Measure time point of outcome:

pre-treatment and 1 week, 2 week,1 month after the treatment

Measure method:

指标中文名:

睡眠质量评分

指标类型:

次要指标

Outcome:

self-rating scale of sleep

Type:

Secondary indicator

测量时间点:

治疗前和治疗后1周、2周、1个月

测量方法:

Measure time point of outcome:

pre-treatment and 1 week, 2 week,1 month after the treatment

Measure method:

指标中文名:

汉密顿焦虑表得分

指标类型:

次要指标

Outcome:

Hamilton Anxiety Inventory score

Type:

Secondary indicator

测量时间点:

治疗前和治疗后1个月

测量方法:

汉密顿焦虑表

Measure time point of outcome:

pre-treatment and1 month after the treatment

Measure method:

Hamilton Anxiety Inventory

指标中文名:

汉密顿抑郁量表得分

指标类型:

次要指标

Outcome:

Hamilton Depression Scale score

Type:

Secondary indicator

测量时间点:

治疗前和治疗后1个月

测量方法:

汉密顿抑郁量表

Measure time point of outcome:

pre-treatment and1 month after the treatment

Measure method:

Hamilton Depression Scale

指标中文名:

生活质量评估量表得分

指标类型:

次要指标

Outcome:

Quality of Life Assessment Scale score

Type:

Secondary indicator

测量时间点:

治疗前和治疗后1个月

测量方法:

生活质量评估量表

Measure time point of outcome:

pre-treatment and1 month after the treatment

Measure method:

QOL-SF36

指标中文名:

治疗前后炎症因子(IL-6、TNF-α)指标

指标类型:

次要指标

Outcome:

Inflammatory factor (IL-6, TNF-α) indices before and after treatment

Type:

Secondary indicator

测量时间点:

治疗前和治疗后2周

测量方法:

炎症因子(IL-6、TNF-α)

Measure time point of outcome:

pre-treatment and 2 weekafter the treatment

Measure method:

Inflammatory factor (IL-6, TNF-α)

指标中文名:

PHN的发生率

指标类型:

次要指标

Outcome:

Incidence of PHN

Type:

Secondary indicator

测量时间点:

治疗前和治疗后3月

测量方法:

Measure time point of outcome:

pre-treatment and 3month after the treatment

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 40 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

受试者符合筛选条件后,利用SPSS软件生成随机数字,分成2组。

Randomization Procedure (please state who generates the random number sequence and by what method):

After the subjects met the screening conditions, SPSS software was used to generate random numbers and divide them into 2 groups.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过邮件向研究负责人索要,项目组根据情况提供。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Data can be requested from the research director by email, and the project team will provide it according to the situation.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集用CRF表,研究者根据受试者的原始观察记录,将数据及时、完整、正确、清晰的载入病例报告表,录入采用相应的数据库系统双人双机录入,之后对数据库进行两边比对。电子数据文件分类保存,并有多个备份保存于不同磁盘或记录介质上,妥善保存,防止循坏。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data were collected on CRF forms, and the investigator loaded the data into the case report form in a timely, complete, correct, and legible manner based on the subject's original observation records, and the entry was done using the appropriate database system of two-person dual entry, after which the databases were compared on both sides. Electronic data files were categorized and saved with multiple backups on different disks or recording media for proper preservation and prevention of deterioration.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-12-27 15:18:04